EXCEDRIN (MIGRAINE RELIEF) Drug Patent Profile

When do Excedrin (migraine Relief) patents expire, and when can generic versions of Excedrin (migraine Relief) launch?

Excedrin (migraine Relief) is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in EXCEDRIN (MIGRAINE RELIEF) is acetaminophen; aspirin; caffeine. There are sixty-six drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the acetaminophen; aspirin; caffeine profile page.

Summary for EXCEDRIN (MIGRAINE RELIEF)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Clinical Trials:	1
DailyMed Link:	EXCEDRIN (MIGRAINE RELIEF) at DailyMed

Recent Clinical Trials for EXCEDRIN (MIGRAINE RELIEF)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Albert Einstein Healthcare Network	Phase 4

See all EXCEDRIN (MIGRAINE RELIEF) clinical trials

Pharmacology for EXCEDRIN (MIGRAINE RELIEF)

Drug Class	Central Nervous System Stimulant Methylxanthine Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Central Nervous System Stimulation Decreased Platelet Aggregation Decreased Prostaglandin Production

US Patents and Regulatory Information for EXCEDRIN (MIGRAINE RELIEF)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998		OTC	Yes	Yes

Expired US Patents for EXCEDRIN (MIGRAINE RELIEF)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998

International Patents for EXCEDRIN (MIGRAINE RELIEF)

See the table below for patents covering EXCEDRIN (MIGRAINE RELIEF) around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	121730	USE OF COMPOSITIONS CONTAINING THE COMBINATION OF ACETAMINOPHEN, ASPIRIN AND CAFFEINE TO ALLEVIATE THE PAIN AND SYMPTOMS OF MIGRAINE
Spain	2198725
Argentina	016337	USO DE UNA COMBINACION DE N-(4-HIDROXIFENIL)ACETAMIDA (ACETOAMINOFENOL,APAP); ACIDO 2-(ACETILOXI)BENZOICO (ASPIRINA ASA) Y 3,7-DIHIDRO-1, 3, 7-TRIMETIL-1H-PURINA-2,6-DIONA (CAFEINA, CAF) Y COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA COMBINACION
World Intellectual Property Organization (WIPO)	9903475

EXCEDRIN (MIGRAINE RELIEF) Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Excedrin Migraine Relief

Introduction to Excedrin Migraine Relief

Excedrin Migraine Relief is a prominent over-the-counter (OTC) medication specifically designed to alleviate migraine headache pain and associated symptoms. The product, which contains a combination of acetaminophen, aspirin, and caffeine, has been a staple in the headache relief market since its FDA approval in 1998[4].

Market Size and Growth

The migraine drugs market, within which Excedrin Migraine Relief operates, is experiencing significant growth. As of 2023, the migraine drugs market size was valued at $4.2 billion and is projected to reach $6.3 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.3% during the period 2024-2032. This growth is driven by advancements in novel therapies and the increasing prevalence of migraines[3].

Competitive Landscape

Excedrin operates in a highly competitive OTC pain relief market, competing with brands like Advil, Tylenol, and Aleve. Despite high awareness levels (99% in the U.S.), Excedrin faced challenges in converting this awareness into sales, particularly in convincing consumers to switch from generalist pain relievers to Excedrin's specialized migraine relief product[1].

Marketing Strategies and Impact

To address these challenges, Excedrin has implemented several innovative marketing strategies:

Social Listening and Limited Edition Packaging

Excedrin used social listening to capture how consumers discuss their headaches and created Limited Edition packaging that reflects these universal headache-inducing moments. This campaign significantly increased consumer engagement, with a 1,000% increase in mentions compared to the previous week. It also led to a three-point lift in purchase intent on Facebook, exceeding the healthcare benchmark of 1.7 points[1].

The Migraine Experience Campaign

In 2016, Excedrin launched "The Migraine Experience" campaign, which utilized a migraine simulator to help non-sufferers understand the severity of migraines. This campaign associated Excedrin with empathy and expertise in migraine relief, resulting in a 22% increase in sales and a substantial conversation lift, with a 300% increase in mentions of Excedrin and head pain[2].

Financial Performance

Excedrin's marketing efforts have translated into notable financial gains:

Sales Growth

The "Migraine Experience" campaign led to Excedrin achieving its highest share, with sales increasing by more than 22% against a category growth of just 1%[2].

Brand Loyalty and Consideration

Excedrin enjoys high loyalty conversion (56%) and awareness (85%), but had to work on driving consumer consideration and trial. The campaigns successfully positioned Excedrin as the go-to brand for migraine relief, increasing branded searches by 38% and overall migraine searches by 20%[2].

Challenges and Setbacks

Despite the successes, Excedrin has faced some challenges:

Production Stoppage

In January 2020, GlaxoSmithKline (GSK) temporarily stopped the production and distribution of Excedrin Extra Strength and Excedrin Migraine due to inconsistencies in ingredient transfer and weighing. This halt, although temporary, could have impacted sales and consumer trust[4].

Ownership and Distribution

Excedrin has undergone several ownership changes. Initially manufactured by Bristol-Myers Squibb, it was acquired by Novartis in 2005. As of March 2015, GSK held majority ownership through a joint venture with Novartis. In July 2022, GSK spun off its consumer healthcare business, including Excedrin, to Haleon[4].

Consumer Engagement and Advocacy

Excedrin's campaigns have not only driven sales but also fostered a strong connection with consumers:

User-Generated Content

The Limited Edition packaging campaign and "The Migraine Experience" led to significant user-generated content and brand love, with consumers even switching from other pain relievers like Advil and Tylenol to Excedrin[1][2].

Workplace Impact

"The Migraine Experience" campaign enabled non-suffering coworkers to understand the plight of migraine sufferers, leading to a deeper empathy and understanding in the workplace. This resulted in nearly 40% of the total video views being driven by consumer sharing and earned coverage[2].

Key Statistics

• Market Size: The migraine drugs market is expected to grow from $4.2 billion in 2023 to $6.3 billion by 2032[3].
• Sales Growth: Excedrin saw a 22% increase in sales following the "Migraine Experience" campaign[2].
• Consumer Engagement: A 1,000% increase in mentions and a three-point lift in purchase intent on Facebook[1].
• Brand Searches: Branded Excedrin searches increased by 38% following the campaign[2].

Conclusion

Excedrin Migraine Relief has navigated the competitive OTC pain relief market through innovative marketing strategies, empathetic campaigns, and a deep understanding of consumer needs. Despite temporary production setbacks, the brand has maintained strong financial performance and consumer loyalty.

"Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients" - GlaxoSmithKline on the temporary production stoppage[4].

Key Takeaways

• Market Growth: The migraine drugs market is projected to reach $6.3 billion by 2032.
• Innovative Marketing: Excedrin's use of social listening and empathetic campaigns has significantly boosted consumer engagement and sales.
• Brand Loyalty: High awareness and loyalty conversion rates contribute to Excedrin's market position.
• Challenges: Temporary production stoppages and competitive market dynamics pose ongoing challenges.

FAQs

Q: What are the active ingredients in Excedrin Migraine Relief? A: Excedrin Migraine Relief contains 250 mg of acetaminophen, 250 mg of aspirin, and 65 mg of caffeine[4].

Q: How has Excedrin's marketing strategy impacted consumer behavior? A: Excedrin's campaigns have led to significant increases in consumer engagement, purchase intent, and brand loyalty, with many consumers switching from other pain relievers to Excedrin[1][2].

Q: What was the impact of "The Migraine Experience" campaign on Excedrin's sales? A: The campaign resulted in a 22% increase in sales and a substantial conversation lift around migraines[2].

Q: Why did Excedrin face a production stoppage in 2020? A: The production stoppage was due to inconsistencies in the transfer and weighing of ingredients during quality control measures[4].

Q: Who currently owns the Excedrin brand? A: As of July 2022, the Excedrin brand is owned by Haleon, following GSK's spin-off of its consumer healthcare business[4].

Sources

1. Excedrin: Universal Pain - MMA Global
2. Excedrin Migraine: Excedrin Works 360 Video - MMA Global
3. Migraine Drugs Market Size to Reach USD 6.3 Billion by 2032 - BioSpace
4. Excedrin (brand) - Wikipedia